Shots:

• The positive recommendation is based on P-III Help Study Open-label Extension assessing Takhzyro (300mg- q2w) in 212 HAE adolescents and adults aged ≥12 yrs.
• The P-III Help study OLE results: reduction rate of attacks- reduction in attacks requiring acute treatment (92.6%)- reduction in mod. to sev. attacks (83.6%)- mean attack rate (87%); 58% & 78% patients showed maximum attack-free period lasted ≥12mos. & ≥6mos. following the first regular treatment dose respectively
• Takhzyro is a mAb targeting plasma kallikrein activity- indicated for the routine prevention of HAE attacks in patients aged ≥12 yrs. and is an approved therapy in multiple countries including the US- EU- Australia and Switzerland with additional ongoing regulatory submission across the globe

Click here to­ read full press release/ article 

Ref: Newswire Canada  | Image: Takeda